Vanguard Capital Management
MGX icon

Vanguard Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Vanguard Capital Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
1,077,700
+19,756
+2% +$26.4K ﹤0.01% 3540
2026
Q1 		$1.42M Buy
+1,057,944
New +$1.64M ﹤0.01% 3475

Other funds holding MGX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management's MGX Position: Q2 2026 in Review

Vanguard Capital Management increased its Metagenomi Therapeutics (MGX) stake by 1.9% in Q2 2026, buying an estimated $26.4K and bringing the position to 1,077,700 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3540.

Vanguard Capital Management first reported a position in MGX in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.42M in Q1 2026. 40 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Vanguard Capital Management held 1,077,700 shares of Metagenomi Therapeutics worth $1.28M as of Q2 2026.
  • Vanguard Capital Management bought 19,756 Metagenomi Therapeutics shares in Q2 2026, an estimated $26.4K.
  • Metagenomi Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3540 holding.
  • Vanguard Capital Management first reported a position in Metagenomi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Metagenomi Therapeutics position peaked at $1.42M in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.